Cybin D/B/A Helus Pharma (HELP) — Stock Price, Chart & Analysis
Cybin D/B/A Helus Pharma (HELP) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $719.64M. Over the past 52 weeks, HELP has traded between $3.76 and $11.62. Cybin D/B/A Helus Pharma does not currently pay a regular dividend. View the live HELP chart, technical opinion, analyst ratings, fundamentals and latest news below.
Cybin D/B/A Helus Pharma (HELP) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $719.64M |
| EPS (TTM) | $-4.44 |
| 52-week high | $11.62 |
| 52-week low | $3.76 |
| Beta | 0.56 |
| Avg. volume | 1.34M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Cybin D/B/A Helus Pharma (HELP)
How much does one share of Cybin D/B/A Helus Pharma cost?
As of the latest update, one share of Cybin D/B/A Helus Pharma (HELP) trades at $100 (+0.00% today).
What is Cybin D/B/A Helus Pharma's market cap?
Cybin D/B/A Helus Pharma has a market capitalization of approximately $719.64M.
What is Cybin D/B/A Helus Pharma's earnings per share (EPS)?
Cybin D/B/A Helus Pharma's trailing twelve-month EPS is $-4.44.
Does Cybin D/B/A Helus Pharma pay a dividend?
Cybin D/B/A Helus Pharma does not currently pay a regular dividend.
What is Cybin D/B/A Helus Pharma's 52-week trading range?
Over the past year, HELP has traded between $3.76 and $11.62.
What is the analyst price target for Cybin D/B/A Helus Pharma?
The mean analyst price target for Cybin D/B/A Helus Pharma is $35.53. This is informational only and not investment advice.
Latest Cybin D/B/A Helus Pharma (HELP) news
- Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed?News · Aug 6, 2026
- Helus Pharma Appoints Michael Halstead as Chief Executive OfficerNews · Aug 3, 2026
- Cybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector AssumptionsNews · Jul 25, 2026
- Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison SilvaNews · Jul 22, 2026
- Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of ScheduleNews · Jul 21, 2026
- Cybin (HELP) Is Up 6.2% After Advancing HLP003 To Phase 3 And Raising US$50 MillionNews · Jul 17, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live HELP dashboard…